Key Highlights
- GSK plc (LSE:GSK) traded marginally higher at about 1,863p on 19 October 2026 after presenting new oncology data.
- Risvutatug rezetecan (Ris-Rez) showed a 61% confirmed objective response rate at the 8 mg/kg dose in relapsed extensive-stage small cell lung cancer.
- The interstitial lung disease rate was low at 2%, supporting a manageable safety profile.
- Pivotal data from the global phase III EMBOLD SCLC-301 trial are expected next year.
GSK plc (LSE:GSK) is one of the FTSE 100 stocks in focus on Monday, 19 October 2026, after the drugmaker presented the first global data for its experimental lung cancer treatment risvutatug rezetecan, known as Ris-Rez. Shares were marginally higher at about 1,863p in morning trading, resilient in a weaker London market. The results add to growing evidence behind a drug that could become an important part of GSK's oncology business.
Why GSK Is in Focus Today
GSK announced on 18 October that Ris-Rez, a B7-H3-targeted antibody-drug conjugate, achieved a confirmed objective response rate of 61% among evaluable patients at the 8 mg/kg dose in the phase Ib dose-optimisation part of the EMBOLD PanTumour-101 trial. At that dose, 11 of 18 patients whose results could be assessed had a confirmed response. The trial focused on patients with relapsed extensive-stage small cell lung cancer.
Safety is a key consideration for this class of drug. The overall rate of interstitial lung disease was 2%, with one moderate case among 50 patients. The data supported the selection of the 8 mg/kg dose being tested in the global phase III EMBOLD SCLC-301 study.
Building on Chinese Phase III Results
The new data build on the ARTEMIS-008 phase III trial run by licensor Hansoh Pharma in China, which met its primary endpoint of overall survival. In that study, Ris-Rez reduced the risk of death by 54% versus topotecan in relapsed small cell lung cancer. These were the first phase III data to show an overall survival benefit for a B7-H3 antibody-drug conjugate in any tumour type, and they were presented at the 2026 World Conference on Lung Cancer.
GSK has exclusive rights to develop and commercialise Ris-Rez outside mainland China, Hong Kong, Macau and Taiwan. The company is advancing a broad clinical programme across lung, prostate and colorectal cancers and plans to begin additional phase III studies.
Why the Market Cares
Small cell lung cancer accounts for about 10% to 15% of lung cancer cases globally and is known for early spread and frequent relapse. Survival with standard treatments is around 12 to 13 months, and five-year survival rates are typically in single digits. A treatment that improves outcomes could address a large unmet need.
For LSE:GSK, oncology is a central growth area as the company prepares for patent expiries in its HIV portfolio later this decade. Positive data on Ris-Rez support the pipeline story and the case that GSK can replace lost revenue with new medicines.
Valuation Context
GSK trades on a trailing price-to-earnings ratio of about 15.6 times, close to its five-year median. The shares have been supported by healthcare's defensive appeal during recent market volatility, with investors rotating away from AI-related sectors.
Market Backdrop on 19 October
The FTSE 100 fell close to 1% on Monday, with banks, miners and defence stocks leading losses after the index's best week in six months. Healthcare names such as GSK attracted relative interest as investors moved away from sectors tied to AI and global growth. A positive scientific update on a promising drug added a company-specific reason for investors to focus on the stock.
What Investors Are Watching Next
The next major event is GSK's third-quarter results, expected around the end of October. Investors will look at sales of key products such as Shingrix, specialty medicines and respiratory treatments, as well as updates on 2026 guidance and the pipeline. Pivotal data from EMBOLD SCLC-301 are expected next year, and the start of further phase III trials in lung and prostate cancer will be watched.
Drug pricing policy in the US, potential tariffs on pharmaceuticals and progress with other late-stage assets will also influence sentiment.
GSK's broader pipeline also includes respiratory, infectious disease and HIV assets, which together support its long-term sales ambitions.
Outlook
GSK plc (LSE:GSK) has strengthened its oncology narrative with encouraging global data for Ris-Rez. While the drug is still in development, today's results support accelerated plans and give investors another reason to track the company's pipeline into its quarterly results.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...